1,2,4-Triazolone Derivative

The present invention provides a 1,2,4-triazolone derivative represented by general formula (1A), which acts as an arginine vasopressin 1b receptor antagonist; a pharmacologically acceptable salt thereof; and a drug containing the same as an active ingredient, particularly a therapeutic or prophylactic agent exhibiting favorable in-vivo disposition in the case of mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorders, hypertension, gastrointestinal disorders, drug dependency, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head trauma, inflammation, immunological disorders, hair loss, and other diseases.

Azole derivative

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor:

1, 2, 4-TRIAZOLONE DERIVATIVE

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia. 4. The 1 claim 1 ,2 claim 1 ,4-triazolone derivative or pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': '1', 'sub': '1-5', 'Ris a Calkyl;'}{'sup': '2', 'Ris a hydrogen atom; and'}{'sup': '3', 'sub': 1-5', '1-5, 'Ris phenyl or pyridyl (the phenyl or pyridyl is optionally substituted by one or two groups selected from the group consisting of Calkyl, Calkoxy, halogen atoms, cyano, hydroxy, trifluoromethyl, difluoromethoxy, and trifluoromethoxy).'}5. The 1 claim 1 ,2 claim 1 ,4-triazolone derivative or pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sub': '1-5', 'A is phenylene, pyridinediyl, or pyrimidinediyl (the phenylene, pyridinediyl, and pyrimidinediyl are optionally substituted by one or two groups selected from halogen atoms and Calkoxy).'}6. The 1 claim 1 ,2 claim 1 ,4-triazolone derivative or pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sub': '1-5', 'A is phenylene or pyridinediyl (the phenylene and pyridinediyl are optionally substituted by one or two groups selected from halogen atoms and Calkoxy).'}8. The 1 claim 1 ,2 claim 1 ,4-triazolone derivative or pharmaceutically acceptable salt thereof according to claim 1 , whereinX is a single bond;n is an integer ...

HETEROAROMATIC RING DERIVATIVE

The compound represented by formula (IA) 2. The heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': '4', 'Rrepresents a halogen atom; and'}{'sup': '5', 'Rrepresents a hydrogen atom or a halogen atom.'}4. The heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1 , whereinX represents a nitrogen atom;{'sup': '2', 'sub': '1-6', 'Rrepresents a Calkyl group;'}{'sup': '3', 'Rrepresents a triazolyl group or a pyrimidinyl group; and'}{'sup': '4', 'Rrepresents a halogen atom.'}5. The heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': '2', 'Rrepresents a methyl group or an ethyl group.'}6. A pharmaceutical composition comprising a heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to as an active ingredient.7. A therapeutic or prophylactic agent for sleep disorder claim 1 , depression claim 1 , anxiety disorder claim 1 , panic disorder claim 1 , schizophrenia claim 1 , drug dependence claim 1 , Alzheimer's disease claim 1 , Parkinson's disease claim 1 , Huntington's disease claim 1 , eating disorder claim 1 , pain claim 1 , digestive system disease claim 1 , epilepsy claim 1 , inflammation claim 1 , immune related disease claim 1 , endocrine related disease claim 1 , or hypertension claim 1 , wherein the agent comprises a heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to as an active ingredient. The present invention relates to a compound having orexin (OX) receptor antagonist activity, a pharmaceutically acceptable salt thereof, and a therapeutic or prophylactic agent containing the compound or the salt as an active ingredient for a disease such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorders, pain, ...

FUSED AZOLE DERIVATIVE

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia. Specifically, the invention provides fused azole derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin 1b receptor: 3. The fused azole derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in Formula (I) claim 1 ,{'sup': '1', 'sub': '1-5', 'Ris Calkyl;'}{'sup': '2', 'sub': '1-5', 'Rrepresents aryl or heteroaryl (the aryl and heteroaryl are optionally substituted by one or two groups selected from the group consisting of Calkoxy and halogen atoms);'}{'sup': 4', '5, 'sub': '1-5', 'Rand Rwhich may be the same or different are each Calkyl; or'}{'sup': 4', '5, 'sub': 1-5', '1-5, 'Rand R, together with the adjoining nitrogen atom, may form a 4- to 8-membered saturated heterocycle optionally containing one or more oxygen atoms in the ring in addition to the adjoining nitrogen atom (the 4- to 8-membered saturated heterocycle is optionally substituted by one or two groups selected from the group consisting of hydroxy and Calkyl, and the 4- to 8-membered saturated heterocycle optionally has a Calkylene group crosslinking two different carbon atoms in the ring), 2-oxa-6-azaspiro[3.3]hept-6-yl, or 2-oxa-7-azaspiro[3.5]non-7-yl;'}{'sup': '6', 'sub': '3-7', 'Ris Ccycloalkyl.'}4. The fused azole derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in Formula (I) claim 1 ,{'sup': '2', 'sub': '1-5', 'Ris phenyl or pyridyl (the phenyl and pyridyl are optionally substituted by one or two groups selected from the group consisting ...

THERAPEUTIC AGENT FOR PARKINSON'S DISEASE

A therapeutic agent for Parkinson's disease containing istradefylline as an effective ingredient being characterized in exhibiting more expression of a shortening effect of the OFF time by administration to a patient of Parkinson's disease of 65 or more years old as compared with administration to a patient of Parkinson's disease of younger than 65 years old. 118-. (canceled)19. A method for more expressing an effect of shortening an OFF time in treatment of Parkinson's disease as compared with the case where a therapeutic agent for Parkinson's disease containing istradefylline as an active ingredient is administered to a patient of Parkinson's disease of younger than 65 years old , comprising administering the therapeutic agent for Parkinson's disease containing istradefylline as an active ingredient to a patient of Parkinson's disease of 65 or more years old.20. The method according to claim 19 , wherein the more expressing the effect of shortening the OFF time is that a rate of a patient where the OFF time is shortened for long time is high.21. The method according to claim 19 , whereinthe effect of shortening the OFF time is that the OFF time is shortened for 1 hour or longer as compared with the case where a placebo is administered, andthe more expressing the effect of shortening the OFF time is that the effect of shortening the OFF time is significantly improved in terms of odds ratio when the agent is administered to a patient of Parkinson's disease of 65 or more years old, as compared to the case where the agent is administered to a patient of Parkinson's disease of younger than 65 years old.22. A method for more expressing an effect of increasing an ON time without troublesome dyskinesia in treatment of Parkinson's disease as compared with the case where a therapeutic agent for Parkinson's disease containing istradefylline as an active ingredient is administered to a patient of Parkinson's disease of younger than 65 years old claim 19 , comprising ...

GLYCINE TRANSPORTER INHIBITOR

The present invention provides novel compounds of formula [I] or pharmaceutically acceptable salts thereof: 3. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Ar is a pyridyl group optionally substituted with one to three substituents selected from substituent group 1.4. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Ar is a pyridyl group substituted with one to three substituents selected from the group consisting of a halogen atom claim 1 , a cyano group claim 1 , a methyl group substituted with one to three halogen atoms claim 1 , and a methoxy group substituted with one to three halogen atoms.5. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris a hydrogen atom.6. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris a Calkyl group claim 1 , or a Chaloalkyl group claim 1 , and Ris a hydrogen atom.7. The compound according to or a pharmaceutically acceptable salt thereof selected from the group consisting of1-[(6-bromo-5-fluoropyridin-2-yl)methyl]-3,3-difluoro-4-[(1S)-1-hydroxyethyl]-1,3-dihydro-2H-indol-2-one,1-[(5-bromo-6-fluoropyridin-3-yl)methyl]-3,3-difluoro-4-[(1S)-1-hydroxyethyl]-1,3-dihydro-2H-indol-2-one,1-(3-chlorobenzyl)-3,3-difluoro-4-[(1S)-1-hydroxyethyl]-1,3-dihydro-2H-indol-2-one,1-[(6-chloro-5-fluoropyridin-2-yl)methyl]-3,3-difluoro-4-[(1S)-1-hydroxyethyl]-1,3-dihydro-2H-indol-2-one,6-({3,3-difluoro-4-[(1S)-1-hydroxyethyl]-2-oxo-2,3-dihydro-1H-indol-1-yl}methyl)-3-fluoropyridine-2-carbonitrile,1-[(6-bromo-5-fluoropyridin-2-yl)methyl]-4-(2,2-difluoro-1-hydroxyethyl)-3,3-difluoro-1,3-dihydro-2H-indol-2-one,3-chloro-6-{[4-(2,2-difluoro-1-hydroxyethyl)-3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl]methyl}pyridine-2-carbonitrile,1-[(6-chloropyridin-2-yl)(2H2)methyl]-3,3-difluoro-4-[(1S)-1-hydroxyethyl]-1,3-dihydro-2H-indol-2-one,3,3-difluoro-4-[(1S)-1-hydroxyethyl]-1-{[5-(trifluoromethyl) ...

AZOLE DERIVATIVE

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. 2. The azole derivative or pharmaceutically acceptable salt thereof according to claim 1 , wherein in the above Formula (I) claim 1 ,{'sup': 4', '5, 'sub': 1-5', '1-5', '3-7', '1-5', '3-7', '1-5', '1-5', '2-5, 'Rand Rwhich may be the same or different each represent a hydrogen atom, Calkyl (the Calkyl is optionally substituted by one to three groups selected from the group consisting of hydroxy, halogen atoms, cyano, Ccycloalkyl, and Calkoxy), Ccycloalkyl, or a 4- to 8-membered saturated or unsaturated heterocycle containing one or more nitrogen, oxygen or sulfur atoms in the ring (the 4- to 8-membered saturated or unsaturated heterocycle is optionally substituted by one or two groups selected from the group consisting of hydroxy, Calkyl, Calkoxy, halogen atoms, cyano, Calkanoyl, and trifluoromethyl), or'}{'sup': 4', '5, 'sub': 1-5', '1-5', '1-5', '2-5', '1-5', '1-5', '1-5, 'Rand R, together with the adjoining nitrogen atom, form a 4- to 8-membered saturated or unsaturated heterocycle optionally containing one or more nitrogen, oxygen or sulfur atoms in the ring in addition to the adjoining nitrogen atom (the 4- to 8-membered saturated or unsaturated heterocycle is optionally substituted by one or two groups selected from the group consisting of hydroxy, Calkyl (the Calkyl is optionally substituted by one or two hydroxyl groups), Calkoxy, halogen atoms, cyano, Calkanoyl, oxo, aminocarbonyl, mono-Calkylaminocarbonyl, di-Calkylaminocarbonyl and trifluoromethyl, and the 4- to 8-membered saturated or unsaturated heterocycle optionally has a Calkylene group crosslinking ...

Process and apparatus for gas phase polymerization of olefins

Process and apparatus for gas phase polymerization of olefins. Olefin gas phase polymerization mainly comprises a combination of (i) use of a new fluidized bed reaction vessel 3 of which the main part has an inverted truncated cone shape equipped with an agitator, (ii) use of a catalyst subjected to a preliminary polymerization treatment and (iii) removal of the polymerization reaction heat mainly by way of the latent heat of vaporization of a liquid organic quenching agent fed as a dispersion through many ports into the fluidized bed consisting of catalyst and polymer particles. According to the process and by use of the apparatus, it becomes possible to carry out the gas phase polymerization easily, continuously and for a long term, and produce good quality polyolefin.

METHOD FOR PRODUCING (ALPHA) -OLEFIN POLYMERS

Process for the polymerization of propylene or for its copolymerization with ethylene or butene- (1) in the presence of a preactivated catalyst

Die Erfindung betrifft ein Verfahren zur Herstellung von α-Olefinpolymeren mit einem hohen Kristallinitätsgrad und guter Teilchenform in hohen Ausbeuten. Die Polymerisation wird in Gegenwart eines voraktivierten Katalysators durchgeführt, der auch besonders geeignet für die Gasphasenpolymerisation oder für eine Gasphasenpolymerisation im Anschluß an eine Aufschlämmungs- oder Substanzpolymerisation ist. Der Katalysator wird hergestellt, indem man ein festes Reduktionsprodukt, das durch Reduktion von TiCl ↓4 mit einer aluminiumorganischen Verbindung erhalten wurde, mit einem Elektronendonor und einem Elektronenakzeptor zu einem Festprodukt umsetzt und dieses Festprodukt dann mit einer aluminiumorganischen Verbindung, einem α-Olefin und einem Reaktionsprodukt aus einer aluminiumorganischen Verbindung mit einem Elektronendonor kombiniert. The invention relates to a process for the preparation of α-olefin polymers having a high degree of crystallinity and good particle shape in high yields. The polymerization is carried out in the presence of a preactivated catalyst which is also particularly suitable for gas phase polymerization or for gas phase polymerization following slurry or bulk polymerization. The catalyst is prepared by reacting a solid reduction product, which was obtained by reducing TiCl ↓ 4 with an organoaluminum compound, with an electron donor and an electron acceptor to form a solid product, and then this solid product with an organoaluminum compound, an α-olefin and a Reaction product of an organoaluminum compound combined with an electron donor.

Process and apparatus for gas phase polymerization of olefins

Vapor-phase polymerization of olefin and equipment therefor

PROCESS FOR THE PREPARATION OF A-OLEFIN POLYMERS

Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson's disease

1,2,4-triazolone derivative

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia. (See Formula 1A)

Novel fuel oil containing amorphous polyolefine

Fused azole derivative

Provided is a therapeutic or prophylactic agent for mood disorders, anxiety, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune related diseases, depilation, and so on. More specifically, provided is a fused azole derivative represented by general formula (I), which has arginine vasopressin 1b receptor antagonism, or a pharmaceutically acceptable salt thereof.

Bidirectional three-dimensional online medical examination system

【課題】運動機能障害患者などにおいても、症状を明確に診断可能な３次元オンライン診療システムを提供する。【解決手段】双方向性３次元オンライン診療システムは、患者側において、音声通話機能及び３次元動作解析機能を有するマーカーレス３次元モーションスキャナーを介して３次元動作情報をスキャンし、得られる３次元動作情報を医療機関に送信するとともに音声通話機能を用いて医療機関と会話し、医療機関側において、患者から送信された３次元動作情報を、音声通話機能及び３次元動作解析機能を有する複合現実のヘッドマウントディスプレイを介してリアルタイムで再構築するとともに音声通話機能を用いて患者と会話する。【選択図】なし

Method for producing (2s)-2-[(1h-pyrazol-1-yl)methyl]-1,3-oxazinane derivative

1,2,4-triazolone derivative

Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinsons disease

1,2,4,-triazolone derivative

1,2,4-triazolone derivative

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia. (See Formula 1A)

Fused azole derivative

1,2,4-triazolone derivative

The disclosure relates to a 1,2,4-triazolone derivative represented by general formula (1A), which acts as an arginine vasopressin 1b receptor antagonist; a pharmacologically acceptable salt thereof; and a drug containing the same as an active ingredient, particularly a therapeutic or prophylactic agent exhibiting favourable in-vivo disposition in the case of mood disorders, anxiety disorders, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, eating disorders, hypertension, gastrointestinal disorders, drug dependency, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head trauma, inflammation, immunological disorders, hair loss, and other diseases. Representative examples of 1,2,4-triazolone derivative are: 2-[3-(3-chlorophenyl)-1-{ 4-[2-(morpholin-4-yl)ethyl]phenyl} -5-oxo-1,5-dihydro-4H-1,2,4- triazol-4-yl]-N-(propan-2-yl)acetamide; 2-[3-(3-chlorophenyl)-1-{ 4-[2-(3-hydroxypyrrolidin-1-yl)ethyl]phenyl} -5-oxo-1,5-dihydro- 4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide; 2-[3-(3-chlorophenyl)-1-(4-{ 2-[3-(hydroxymethyl)pyrrolidin-1-yl] ethyl} phenyl)-5-oxo-l,5- dihydro-4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide; and 2-[3-(3-chlorophenyl)-1-{ 4-[2-(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl} -5-oxo- 1,5-dihydro-4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide.

Preparation of alpha-olefin polymer

1,2,4-triazolone derivative

Heteroaromatic ring derivative

The compound represented by formula (IA) or a pharmaceutically acceptable salt thereof is based on orexin (OX) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.

Azole derivative

Azole derivative

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor:

Fused azole derivative

Provided is a therapeutic or prophylactic agent for mood disorders, anxiety, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune related diseases, depilation, and so on. More specifically, provided is a fused azole derivative represented by general formula (I), which has arginine vasopressin 1b receptor antagonism, or a pharmaceutically acceptable salt thereof.

Methods for detecting mild cognition impairment

【課題】軽度認知障害（ＭＣＩ）の検出方法の提供。【解決手段】被験者から採取された生体試料由来のゲノムＤＮＡにおける標的ＣｐＧサイトのＤＮＡメチル化率を測定することを含む、当該被験者における軽度認知障害（ＭＣＩ）の検出方法であって、前記標的ＣｐＧサイトが、染色体上の特定の位置又はその近傍に位置するＣｐＧサイトからなる群より選択される少なくとも１つのＣｐＧサイトである、方法。前記ゲノムＤＮＡがバイサルファイト処理されたゲノムＤＮＡである方法。前記ＤＮＡメチル化率の測定がマイクロアレイ法、パイロシークエンス法、バイサルファイトシークエンス法、又は定量的メチル化特異的ＰＣＲ（ＭＳＰ）法を用いて行われる方法。【選択図】なし

DERIVATIVE OF AZOLO

Azole derivative

The invention according to the present application provides a therapeutic or prophylactic agent for diseases including mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, digestive diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammations, immune-related diseases and alopecia. Specifically provided is an azole derivative having an arginine-vasopressin 1b receptor antagonistic activity and represented by general formula (I) or a pharmaceutically acceptable salt thereof.

パーキンソン病診断指標

【課題】パーキンソン病の早期から鑑別診断可能な簡易診断マーカーの提供。【解決手段】パーキンソン病を診断する目的で、生体由来試料中の中鎖〜長鎖アシルカルニチン及び２次胆汁酸から選ばれる成分の濃度を測定する方法。【選択図】なし

ソフトウェア試験項目抽出方法、ソフトウェア試験項目抽出装置および記録媒体

(57)【要約】 【課題】 ソフトウェア試験を実施する際、試験項目を 過不足なく自動的に抽出することができるようにする。 【解決手段】 プログラムモジュール入力部１から入力 された母体プログラムモジュールおよび改版プログラム モジュールに対して、処理分岐点ラベル付与部２におい てそれぞれ別個にラベルを付与し、分岐点ラベル付プロ グラムモジュール記憶部３に記憶する。そして、記憶さ れたこれらのプログラムモジュールを読み出して試験ポ イント抽出部４で試験ポイントを抽出し、この抽出結果 に基づいて試験項目を試験ポイント一覧生成・出力部５ から出力する。

Stroke diagnosis and therapy assistance system, stroke state information providing device, and stroke state information providing program

[Problems] Provision of a system for assisting diagnosis/treatment of stroke which can easily provide supportive information so that the type of stroke can be determined appropriately and corresponding treatment strategy can be implemented. [Solutions] When the device for assisting diagnosis/treatment of stroke 101 acquires information of CT images, DWI, ADCmap, and MRA images indicating state of stroke from the device for providing information about state of stroke 103 , it uses the acquired information of images and the information about laboratory findings to determine the type of stroke in a unit of stroke type determiner trained to use the predetermined information of images and the predetermined information about laboratory findings to determine the type of stroke corresponding thereto. The device for providing information about state of stroke 103 provides each information of images indicating state of stroke of a subject being diagnosed, to the device for assisting diagnosis/treatment of stroke 101 , acquires and displays the type of stroke and therapeutic strategy determined from the device for assisting diagnosis/treatment of stroke 101.

アゾール誘導体を含有する医薬

【課題】気分障害、不安障害、統合失調症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、高血圧、消化器疾患、薬物依存症、てんかん、脳梗塞、脳虚血、脳浮腫、頭部外傷、炎症、免疫関連疾患、脱毛症等の疾患において良好な体内動態を示す治療又は予防剤の提供。 【解決手段】アルギニン−バソプレッシン１ｂ受容体拮抗作用を有する、一般式（Ｉ）で表されるアゾール誘導体、又はその医薬上許容される塩を有効成分として含有する気分障害、不安障害、統合失調症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、高血圧、消化器疾患、薬物依存症、てんかん、脳梗塞、脳虚血、脳浮腫、頭部外傷、炎症、免疫関連疾患、脱毛症等の疾患の治療又は予防剤。 【選択図】なし

パーキンソン病診断薬及びモデル動物

【課題】パーキンソン病の新たな原因遺伝子の提供及び新たなモデル動物の提供。【解決手段】パーキンソン病の遺伝子検査方法であって、被験者由来の試料におけるプロサポシン遺伝子変異を検出する方法。【選択図】なし

Stroke diagnosis and therapy assistance system, stroke state information providing device, and stroke state information providing program

[Problems] Provision of a system for assisting diagnosis/treatment of stroke which can easily provide supportive information so that the type of stroke can be determined appropriately and corresponding treatment strategy can be implemented. [Solutions] When the device for assisting diagnosis/treatment of stroke 101 acquires information of CT images, DWI, ADCmap, and MRA images indicating state of stroke from the device for providing information about state of stroke 103 , it uses the acquired information of images and the information about laboratory findings to determine the type of stroke in a unit of stroke type determiner trained to use the predetermined information of images and the predetermined information about laboratory findings to determine the type of stroke corresponding thereto. The device for providing information about state of stroke 103 provides each information of images indicating state of stroke of a subject being diagnosed, to the device for assisting diagnosis/treatment of stroke 101 , acquires and displays the type of stroke and therapeutic strategy determined from the device for assisting diagnosis/treatment of stroke 101.

神経疾患の治療薬およびそのスクリーニング方法

【課題】 神経疾患の治療薬およびそのスクリーニング方法 【解決手段】 被検化合物の存在下および非存在下のそれぞれの条件において、細胞を培養する工程と、それぞれの培養した細胞中のＬＭＯ３遺伝子の発現量を測定する工程と、被検化合物の存在下において培養した細胞中のＬＭＯ３遺伝子の発現量が、被検化合物の非存在下において培養した細胞中のＬＭＯ３遺伝子の発現量よりも低い場合に、当該被検化合物を神経疾患の治療薬と判定する工程と、を備える、神経疾患の治療薬のスクリーニング方法を提供する。 【選択図】 なし

パーキンソン病の診断

【課題】常染色体優性遺伝性パーキンソン病の診断手段の提供。 【解決手段】常染色体優性遺伝性パーキンソン病を診断する目的で、生体試料のＣＨＣＨＤ２中の突然変異を検出する方法。 【選択図】なし

パーキンソン病予防治療剤

【課題】ドパミン作用補充療法薬ではなく、神経細胞死回復作用を有するパーキンソン病予防治療剤の提供。 【解決手段】次式（１） で表される化合物又はその塩を有効成分とするパーキンソン病予防治療剤。 【選択図】なし

タウオパチーの鑑別診断法

【課題】タウオパチーのうち、大脳皮質基底核変性症とＰＳＰとを区別して容易に診断できる方法を提供すること。【解決手段】ヒト由来の検体にヒトタウ蛋白のＡ１６８から始まるＣ末断片のＮ末側を認識する抗体及びヒトタウ蛋白のＮ３６８で切断されたＮ末断片のＣ末側を認識する抗体を反応させることを特徴とする、ヒト検体中の大脳皮質基底核変性症に特異的なタウ断片の検出方法。【選択図】なし

パーキンソン病治療剤

【課題】新たなパーキンソン病治療剤の提供。【解決手段】胆汁酸類を有効成分とするパーキンソン病治療剤。【選択図】なし